Romulus K. Brazzell - Jan 6, 2025 Form 4/A - Amendment Insider Report for KALA BIO, Inc. (KALA)

Role: Head of Research and Development and Chief Medical Officer
Signature: /s/ Mary Reumuth, Attorney-in-Fact
Stock symbol: KALA
Transactions as of: Jan 6, 2025
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 1/10/2025, 08:00 PM
Date Of Original Report: Jan 7, 2025
Previous filing: Jun 27, 2024
Next filing: Jun 4, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	KALA	Common Stock						91.6K	Jan 6, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amendment is being filed solely to amend the securities as beneficially owned by the reporting person following the transactions previously reported on January 7, 2025. On January 7, 2025, the reporting person filed a Form 4 which inadvertently reported that, following the grant of restricted units and a sale of common stock, the reporting person held 92,418 shares. As reported in this amendment, the reporting person directly owned 91,636 shares of common stock following the transactions, which included 62,961 unvested restricted stock units.

Content

This amendment is being filed solely to amend the securities as beneficially owned by the reporting person following the transactions previously reported on January 7, 2025. On January 7, 2025, the reporting person filed a Form 4 which inadvertently reported that, following the grant of restricted units and a sale of common stock, the reporting person held 92,418 shares. As reported in this amendment, the reporting person directly owned 91,636 shares of common stock following the transactions, which included 62,961 unvested restricted stock units.

Remarks:

Head of Research and Development and Chief Medical Officer